Menu
Boston, MA, USA, and Lausanne, SWITZERLAND, February 11, 2021 – SOPHiA GENETICS, a global leader in Data-Driven Medicine, has appointed Ross Muken as Chief Financial Officer (CFO). Mr. Muken brings more than 20 years of financial leadership experience with a strong focus on the medical technology and life sciences space. He joins the SOPHiA GENETICS team from Click Therapeutics where he served as CFO and Chief Operating Officer (COO).
“I am delighted to welcome Ross to our team. His leadership and experience across the life science industry will be invaluable as we continue to advance our mission to develop and commercialize data analytics solutions,” said Jurgi Camblong, CEO and Founder of SOPHiA GENETICS. “Ross is joining SOPHiA at an exciting time as the overall demand for Data-Driven Medicine is rapidly growing. I look forward to his contributions as we enter into our next phase of growth.”
“I am thrilled to join the SOPHiA GENETICS team and am eager to contribute to their efforts to make the global healthcare system more sustainable,” said Ross Muken, CFO of SOPHiA GENETICS. “I believe that digital technologies are the key to unlocking the era of Data-Driven Medicine, which will allow patients all over the world to receive equal access to better diagnoses and treatments. I look forward to applying my expertise to help advance this vitally important effort to deliver better outcomes to the global healthcare community and positively impact human health.”
Ross Muken
Mr. Muken was most recently the CFO and COO of Click Therapeutics. Before joining Click, he was Partner, Senior Managing Director and Head of the Healthcare Services & Technology Research Team at Evercore ISI where he covered more than 50 companies across the Healthcare Technology & Distribution, Life Science Tools & Diagnostics, Managed Care & Facilities and Medical Supplies & Devices sub-sectors. Prior to joining Evercore ISI, Mr. Muken served as a Managing Director at Deutsche Bank Securities and spent time in the Equity Research division of Thomas Weisel Partners. He began his career as an M&A Investment Banker at Bank of America Securities after earning his B.S. in Business Administration, magna cum laude, at Boston University.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
